Global Transdermal Drug Delivery System Market 2018-2023: Opportunities with Collaborations Between Pharmaceutical Companies and Drug Delivery Firms

News provided by

Jan 14, 2019, 09:15 ET

DUBLIN, Jan 14, 2019 /PRNewswire/ --

The "Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The transdermal drug delivery systems market is expected to reach 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period.

Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are expected to support market growth in the coming years. However, drug failures and recalls of transdermal drug delivery systems are expected to restrain market growth to a certain extent.

By application, the pain management segment is expected to grow at the highest rate during the forecast period.

On the basis of application, the transdermal drug delivery systems market is segmented into five broad categoriespain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). The pain management segment is expected to grow at the highest CAGR during the forecast period owing to the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.

The transdermal patches segment is expected to dominate the market in 2018.

On the basis of type, the transdermal drug delivery systems market is segmented into transdermal patches and transdermal semisolids. In 2018, the transdermal patches segment is expected to account for a dominant share of the transdermal drug delivery systems market. This drug delivery system offers several advantages, such as reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch. Also, the use of patches results in increased patient compliance due to their non-invasive nature and painless application. These factors are expected to drive market growth.

The North American transdermal drug delivery systems market is expected to grow at the highest CAGR during the forecast period.

North America, comprising the US and Canada, offers high-growth opportunities for players in the transdermal drug delivery systems market. This segment is slated to register the highest CAGR during the forecast period. Some of the factors driving market growth in the North American region are rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.

The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Transdermal Drug Delivery Systems Market Overview
4.2 Transdermal Drug Delivery Systems Market, By Type, 2018
4.3 Transdermal Drug Delivery Systems Market, By Type, 2018
4.4 Transdermal Drug Delivery Systems Market: Geographic Snapshot

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Prevalence of Chronic Diseases
5.2.1.2 Technological Advancements in Transdermal Drug Delivery Systems
5.2.2 Restraints
5.2.2.1 Drug Failure and Recalls of Transdermal Drug Delivery Systems
5.2.3 Opportunities
5.2.3.1 Collaborations Between Pharmaceutical Companies and Drug Delivery Firms
5.2.3.2 Self-Administration and Home Care Drug Delivery Systems
5.2.4 Challenges
5.2.4.1 Technical Barriers Related to Skin Irritation and Permeability

6 Transdermal Drug Delivery Systems Market, By Type
6.1 Introduction
6.2 Transdermal Patches
6.2.1 Drug-In-Adhesive Patches
6.2.2 Matrix Patches
6.2.3 Reservoir Membrane Patches
6.2.4 Microneedle Patches
6.3 Transdermal Semisolids
6.3.1 Gels
6.3.2 Ointments
6.3.3 Sprays

7 Transdermal Drug Delivery Systems Market, By Application
7.1 Introduction
7.2 Pain Management
7.2.1 Pain Management to Account for the Largest Share of the Transdermal Drug Delivery Systems Market
7.3 Hormonal Applications
7.3.1 Testosterone Replacement Therapy
7.3.1.1 Skin Irritation, Poor Absorption of Drugs, High Costs, and the Need for Frequent Dosing are Factors Limiting Market Growth
7.3.2 Transdermal Estrogen Therapy
7.3.2.1 Growing Use of Transdermal Contraceptive Patches is Likely to Drive the Market for Transdermal Estrogen Therapy
7.4 Central Nervous System Disorders
7.4.1 Increasing Incidence of Parkinson's and Alzheimer's Disease to Drive the Market for Central Nervous System Disorders
7.5 Cardiovascular Diseases
7.5.1 Availability of Alternative and Advanced Drug Delivery Options to Limit Market Growth
7.6 Other Applications
7.6.1 Increasing Demand for Advanced Transdermal Microneedle Patches for Diabetes ManagementA Key Market Driver

8 Transdermal Drug Delivery Systems Market, By End User
8.1 Introduction
8.2 Home Care Settings
8.3 Hospitals & Clinics

9 Transdermal Drug Delivery Systems Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 Rising Prevalence of Targeted Disease and Development of Technologically Advanced Transdermal Drug Delivery SystemsKey Factors Driving Market Growth
9.2.2 Canada
9.2.2.1 Rising Prevalence of Chronic Diseases and Funding for the Development of Transdermal Drug Delivery Systems to Drive Market Growth
9.3 Europe
9.3.1 Germany
9.3.1.1 Growing Focus of Pharmaceutical Companies in Germany on the Development of Transdermal Products to Drive Market Growth
9.3.2 UK
9.3.2.1 Increasing Funding for the R&D of Innovative Transdermal Technologies to Drive Market Growth
9.3.3 France
9.3.3.1 Development of Transdermal Drug Delivery Systems By Local Players to Support Market Growth
9.3.4 RoE
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Increasing Number of Product Approvals and Growing Focus of Local Players on R&D of Transdermal Systems to Support Market Growth
9.4.2 China
9.4.2.1 Growing Focus of Major Players in China Towards the Development of Transdermal Drug Delivery Systems to Drive Market Growth
9.4.3 India
9.4.3.1 Growing Awareness Among Healthcare Providers and Patients and Increasing Focus on Noninvasive Methods of Drug Delivery to Drive Market Growth
9.4.4 Ropac
9.5 RoW

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis
10.3 Market Share Analysis, By Application
10.3.1 Pain Management
10.3.2 Hormonal Applications
10.3.3 Central Nervous System Disorders
10.3.4 Cardiovascular Diseases
10.4 Competitive Scenario
10.4.1 Product Launches and Approvals
10.4.2 Expansions
10.4.3 Agreements and Collaborations
10.4.4 Acquisitions

11 Company Profiles
11.1 Hisamitsu Pharmaceutical Co., Inc.
11.2 Mylan N.V.
11.3 UCB S.A.
11.4 Novartis AG
11.5 Glaxosmithkline PLC
11.6 Boehringer Ingelheim International GmbH
11.7 Johnson & Johnson (J&J)
11.8 Endo International, Inc.
11.9 Purdue Pharma L.P.
11.10 Lavipharm
11.11 Lead Chemicals Co., Inc.
11.12 Luye Pharma Group

For more information about this report visit https://www.researchandmarkets.com/research/488pmq/glonal?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets